Home / Market News / $VRDN
fiscal.ai Corporate Catalyst Impact 55/100 ● positive

Wedbush Increases Price Target for Viridian Therapeutics to $42

Nov 5, 2026, 7:14 PM UTC · Primary ticker $VRDN

Wedbush has increased its price target for Viridian Therapeutics to $42 from $41, maintaining an 'Outperform' rating. This adjustment suggests a potential upside of 44.6% from the company's recent closing price, indicating a positive outlook from the analyst firm.

Wedbush, an analyst firm, has raised its price target for Viridian Therapeutics (VRDN) from $41 to $42 while reiterating its 'Outperform' rating. This action signals continued confidence in the company's prospects and suggests that the analyst believes the stock has significant room for growth, projecting a 44.6% upside. For traders, this could be seen as a positive signal, potentially leading to increased buying interest in the short term. The long-term implications depend on whether Viridian Therapeutics can meet or exceed the expectations embedded in this new price target, particularly regarding its clinical pipeline and commercialization efforts. A key opportunity for traders lies in the potential for a short-term price bump following this analyst upgrade, though the risk remains that the market may not fully embrace the new target or that future company news could negate this positive sentiment.

$VRDN positive Price target increase and maintained 'Outperform' rating
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.